Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
about
Ceftobiprole medocaril in the treatment of hospital-acquired pneumoniaCeftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.
P2860
Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Synergistic activity of ceftob ...... mediate Staphylococcus aureus.
@ast
Synergistic activity of ceftob ...... mediate Staphylococcus aureus.
@en
type
label
Synergistic activity of ceftob ...... mediate Staphylococcus aureus.
@ast
Synergistic activity of ceftob ...... mediate Staphylococcus aureus.
@en
prefLabel
Synergistic activity of ceftob ...... mediate Staphylococcus aureus.
@ast
Synergistic activity of ceftob ...... mediate Staphylococcus aureus.
@en
P2093
P2860
P356
P1476
Synergistic activity of ceftob ...... mediate Staphylococcus aureus.
@en
P2093
A Simon Lynch
Alfred M Barron
Anne Marie Queenan
Darren Abbanat
James Hastings
Jeffrey Fernandez
John L Melton
Karen Amsler
Wenchi Shang
Wenping He
P2860
P304
P356
10.1128/AAC.06057-11
P407
P577
2012-01-09T00:00:00Z